Patient characteristics
| . | n (%) . |
|---|---|
| Number of cases | 141 |
| Sex | |
| Male | 103 (73) |
| Female | 38 (27) |
| Age at diagnosis, y | |
| <70 | 55 (39) |
| ≥70 | 86 (61) |
| FAB | |
| RA | 47 (33) |
| RARS | 27 (19) |
| RAEB | 48 (34) |
| RAEBT | 5 (4) |
| RCUD/MD | 4 (3) |
| CMML | 7 (5) |
| Other | 3 (2) |
| IPSS-R* | |
| Very low | 23 (21) |
| Low | 31 (28) |
| Intermediate | 20 (18) |
| High | 24 (21) |
| Very high | 14 (13) |
| Cytogenetics† | |
| Normal | 89 (63) |
| Abnormal, not complex | 41 (29) |
| Complex | 11 (8) |
| Blood counts, median (range) | |
| White blood cell, ×109/L | 3.7 (0.9-95.2) |
| ANC, ×109/L | 1.6 (0.1-28) |
| Hemoglobin, g/dL | 9.7 (5.8-15.2) |
| Platelet, ×109/L | 102 (6-987) |
| Bone marrow blast, %‡ | 1 (0-28) |
| Treatment during follow-up | |
| Azacitidine | 28 (20) |
| Decitabine§ | 20 (14) |
| . | n (%) . |
|---|---|
| Number of cases | 141 |
| Sex | |
| Male | 103 (73) |
| Female | 38 (27) |
| Age at diagnosis, y | |
| <70 | 55 (39) |
| ≥70 | 86 (61) |
| FAB | |
| RA | 47 (33) |
| RARS | 27 (19) |
| RAEB | 48 (34) |
| RAEBT | 5 (4) |
| RCUD/MD | 4 (3) |
| CMML | 7 (5) |
| Other | 3 (2) |
| IPSS-R* | |
| Very low | 23 (21) |
| Low | 31 (28) |
| Intermediate | 20 (18) |
| High | 24 (21) |
| Very high | 14 (13) |
| Cytogenetics† | |
| Normal | 89 (63) |
| Abnormal, not complex | 41 (29) |
| Complex | 11 (8) |
| Blood counts, median (range) | |
| White blood cell, ×109/L | 3.7 (0.9-95.2) |
| ANC, ×109/L | 1.6 (0.1-28) |
| Hemoglobin, g/dL | 9.7 (5.8-15.2) |
| Platelet, ×109/L | 102 (6-987) |
| Bone marrow blast, %‡ | 1 (0-28) |
| Treatment during follow-up | |
| Azacitidine | 28 (20) |
| Decitabine§ | 20 (14) |
CMML, chronic myelomonocytic leukemia; FAB, French-American-British classification system; RA, refractory anemia; RAEB, refractory anemia with excess blasts; RAEBT, refractory anemia with excess blasts in transformation; RARS, refractory anemia with ring sideroblasts; RCUD/MD, refractory cytopenia with unilineage/multilineage dysplasia.
Twenty-nine patients were missing data for 1 or more variables in the IPSS-R and could not be classified.
Several patients had incomplete cytogenetic information so we stratified them into known groups.
Twenty patients had missing data for bone marrow blast percent; these patients were excluded from survival modeling.
One decitabine treated patient stopped treatment after 1 cycle.